Dmitriy N. Feldman, M.D.

Interventional Cardiology
Dmitriy Feldman

Our group of experienced interventional cardiologists and vascular/endovascular specialists offers a comprehensive, multispecialty, cutting-edge approach to the evaluation and care of patients with coronary, peripheral and carotid arterial disease, with an emphasis on a minimally invasive endovascular approach. As an academic interventionalist, researcher and educator my goal is to deliver the best possible care to our patients and to provide them with access to the most innovative, state-of-the-art technology for treatment of coronary, peripheral vascular and carotid disease.

Dr. Dmitriy N. Feldman is the Director of Endovascular Service of Interventional Cardiac and Endovascular Laboratory in the Division of Cardiology. He graduated Summa Cum Laude from New York University in December 1996 and received his Doctorate of Medicine degree from the Mount Sinai School of Medicine May 2001 in New York City. He completed his medical internship, residency in Internal Medicine, fellowship in Clinical Cardiology, and Interventional Cardiology Fellowship training at New York Presbyterian Hospital, Weill Cornell Medical College in New York City. He is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Endovascular Medicine.

Dmitriy N. Feldman, M.D. is an Interventional Cardiologist specializing in angioplasty and stenting and one of Cornell's leaders in management of cardiovascular and peripheral vascular diseases on both inpatient and outpatient basis. His clinical expertise extends from the performance of complex coronary interventions to endovascular treatment of peripheral and carotid disease. His areas of research interest include percutaneous coronary and endovascular intervention outcomes research and he has performed extensive work with the New York State Department of Health PCI database, American College of Cardiology National Cardiovascular Data Registry as well as the Cornell Catheterization Laboratory institutional database. His area of research expertise includes the use of peri-procedural pharmacological agents, particularly bivalirudin, glycoprotein IIb/IIIa inhibitors, and thienopyridines. Dr. Feldman's research activities have been published in high impact journals such as Circulation, the Journal of American College of Cardiology, American Heart Journal, American Journal of Cardiology, and he has presented his findings at numerous national meetings including American Heart Association, American College of Cardiology, and Transcatheter Cardiovascular Therapeutics. He also serves as a peer reviewer for major high-impact medical journals such as Circulation, the LANCET and others.

Dmitriy N. Feldman, MD is a member of multiple professional societies: Fellow of American College of Cardiology (FACC), Fellow of Society for Cardiovascular Angiography and Interventions (FSCAI), Member of American Heart Association, Doctorate of Society for Vascular Medicine. He serves on Society for Cardiovascular Angiography and Interventions (SCAI) PVD committee and has been a passionate advocate in emphasizing importance of PVD and endovascular therapies. He has participated in writing consensus/expert documents with SCAI and ACC in the fields of coronary and peripheral vascular disease. Dr. Feldman has served as a principal investigator and coinvestigator on numerous trials and registries in coronary, structural heart, peripheral vascular and carotid disease areas of research. Dr. Feldman is one of Cornell's leaders in managing patients with resistant/refractory hypertension and evaluating novel percutaneous renal denervation therapy for those patients. He serves as a member of the Institutional Protocol Review Committee for Therapeutic and Interventional Studies and member of Vascular Service Line, Peripheral Intervention Quality Committee.


Dr. Feldman is currently appointed as a Director of Endovascular Cardiology Center for Vascular Care, an Assistant Professor of Medicine and an Assistant Attending Physician in the Interventional Cardiac and Endovascular Laboratory of the Greenberg Division of Cardiology.


A summary of Dr. Feldman's Education, Training and/or Faculty Appointments is listed as following:

2001 M.D. - The Mount Sinai School of Medicine

2002 Internship, Internal Medicine - NYPH - Cornell Campus

2004 Residency, Internal Medicine - NYPH - Cornell Campus

2007 Fellowship, Cardiology - NYPH - Cornell Campus

2008 Fellowship, Interventional Cardiology - NYPH - Cornell Campus


Other: Fellow, American College of Cardiology

Fellow, Society for Cardiovascular Angiography and Interventions

Doctorate, Society for Vascular Medicine


*Please note that Dr. Feldman is fluent in Russian.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


  1.  Swaminathan RV, Wang TY, Kaltenbach LA, Kim LK, Minutello RM, Bergman G, Wong SC, Feldman DN. Nonsystem Reasons for Delay in Door-To-Balloon Time and In-Hospital Mortality: A Report from the National Cardiovascular Data Registry. J Am Coll Cardiol 2013;61:1688-95.
  2. Blankenship JC, Gigliotti OS, Feldman DN, Mixon TA, Patel RAG, Sorajja P, Yakubov SJ, Chambers CE. Ad Hoc Percutaneous Coronary Intervention:  A Consensus Statement from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013;81:748-58.
  3. Midwall S, Swaminathan RV, Charitakis K, Kim LK, Gordin J, Hriljac I, Minutello RM, Bergman G, Wong SC, Feldman DN. Impact of peripheral vascular disease on short- and long-term outcomes in patients undergoing non-emergent percutaneous coronary intervention in the drug-eluting stent era. J Invasiv Cardiol 2013;25:132-6.
  4. Yang DC, Swaminathan RV, Kim LK, Feldman DN. Pharmacotherapy for the reduction of stent thrombosis. Expert Rev of Cardiovasc Ther 2013;11:567-76.
  5. Swaminathan RS, Kim LK, Charitakis KN, Feldman DN. Arteriovenous fistula rescue via endovascular treatment of ipsilateral subclavian artery stenosis utilizing a retrograde wiring approach from the fistula access site. Vascular Disease Management 2013:10:E11-E15. 
  6. Gordin JS, Haider A, Swaminathan RV, Kim LK, Minutello RM, Bergman G, Wong SC, Feldman DN. The impact of chronic statin therapy on peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention. Am J Cardiol 2012;110:1397-404.
  7. Armstrong EJ, Feldman DN, Wang TY, Kaltenbach LA, Yeo KK, Wong SC, Spertus J, Shaw RE, Minutello RM, Moussa I, Ho KKL, Rogers JH, Shunk KA. Clinical Presentation, Management and Outcomes of Angiographically-Documented Early, Late and Very Late Stent Thrombosis. J Am Coll Cardiol Interv 2012;5:131-40.
  8. Ghosh R, Swaminathan RV, Kim LK, Feldman DN. Reperfusion therapy in ST-elevation myocardial infarction: guidelines, strategies, pharmacology, and stent selection. Minerva Medica 2012;103:431-439.
  9. Baklanov DV, Kaltenbach LA, Marso SP, Subherwal SS, Feldman DN, Garratt KN, Curtis JP, Messenger JC, Rao SV. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol 2012;61:420-6.
  10. Wong SC, Kim L, Feldman DN. Review of ExoSeal and vascular closure devices. Cardiac and Vascular Update 2012;3:10-13.
  11. Subherwal S, Peterson ED, Dai D, Thomas L, Messenger J, Xian Y, Brindis RG, Feldman DN, Senter S, Klein LW, Marso SP, Roe MT, Rao SV. Temporal Trends in and Factors Associated with Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data CathPCI Registry. J Am Coll Cardiol 2012;59:1861-9.
  12. Shah A, Feldman DN. Outcomes of the HORIZONS-AMI trial: bivalirudin enhances survival in heart attack patients undergoing angioplasty after 3 years.  Vascular Health and Risk Management 2012;8:115-123.
  13. Kim LK, Swaminathan VR, Charitakis, K, Feldman DN. Novel anti-platelet therapies. Curr Atheroscler Rep 2012;14:78-84.
  14. Gojraty S, Feldman DN. Choice of drug-eluting stents. The Medical Letter on Drugs and Therapeutics 2012;1406b. 
  15. Charitakis K, Swaminathan RV, Kim L, Feldman DN. Endovascular treatment of coronary-subclavian steal syndrome. Vascular Disease Management 2011;8:E207-210. 
  16. Feldman DN, Kim L, A. Garvey Rene, Minutello RM, Wong SC. Prognostic value of cardiac troponin-I or troponin-T elevation following elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2011,77:1020-30.
  17. Avgerinos DV, Feldman DN, Salemi A. Unplanned staged hybrid management of post-myocardial infarction ventricular septal defect. Submitted, Cardiology 2011;118:38-41.
  18. Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy of high-dose clopidogrel treatment (600-mg) <2 hours prior to percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 2010;105:323-332.
  19. Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Catheter Cardiovasc Interv 2010;76:513-24.
  20. Feldman DN. Angina relief with percutaneous coronary intervention versus medical therapy for chronic stable angina. Evid Based Med 2010;15:105-6.
  21. Kim LK, Wong SC, Minutello RM, Bergman G, Feldman DN. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice. J Invasive Cardiol 2010;22:94-100. 
  22. Minutello, RM, Kim LK, Aggarwal S, Cuomo L, Feldman DN, Wong SC. Door-to-balloon-time in primary percutaneous coronary intervention predicts degree of myocardial damage as measured using cardiac biomarkers. Tex Heart Inst J 2010;37:161-165.
  23. Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short and long-term outcomes. Am J Cardiol 2009;104:1210-1215.
  24. Feldman DN, Moussa ID. Efficacy of aspirin for secondary prevention in patients with peripheral artery disease. Expert Review of Cardiovasc Therapy 2009;7:1203-1207.
  25. Feldman DN, Wong SC, Bergman G, Minutello RM. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. J Invasive Cardiol 2009;21:258-263.
  26. Almaani S, Feldman D, Moussa ID. Retrograde recanalization of an occluded popliteal artery. Challenging cases. Endovascular today 2009;Feb:38-40.
  27. Gade CL, Lin F, Feldman DN, Weinsaft JW, Min JK. Assessment of coronary artery aneurysm after stent placement for myocardial infarction: evaluation by multidetector computed tomography. J Cardiovasc Computed Tomography 2008;2:117-9.
  28. Feldman DN, Gade CL, Gidseg DS, Parikh M, Bergman G, Wong SC, Minutello RM. Impact of bivalirudin on outcomes following percutaneous coronary revascularization with drug-eluting stents. Am Heart J 2007;154:695-701.
  29. Feldman DN, Minutello RM, Gade CL, Wong SC. Outcomes following immediate (ad hoc) versus staged percutaneous coronary interventions (report from the 2000-2001 New York State Angioplasty Registry). Am J  Cardiol 2007;99:446-9.
  30. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, Wong SC. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007;20:458-65.
  31. Feldman DN, Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong SC, Minutello RM. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60-80, and >80 years)(from the New York State Angioplasty Registry). Am J Cardiol 2006;98:1334-9.
  32. Polin N, Feldman D, Naidu S. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: novel application of the cutting balloon. J Invasive Cardiology 2006;18:436-7.
  33. Feldman DN, Campagna R. Images in cardiology: macroscopic T-wave alternans. ClinCardiol2006;29:422.
  34. Feldman DN, Roman MJ. Aneurysms of the Sinuses of Valsalva. Cardiology 2006;106:73-81.
  35. Minutello RM, Bhagan S, Feldman D, Sharma A, Hong MK, Wong SC. Angiographic pattern of restenosis following implantation of overlapping sirolimus-eluting (cypher) stents. Am J Cardiol 2006;97:499-501.
  36. Feldman DN, Gade CL, Roman MJ. Ruptured aneurysm of the right sinus of Valsalva associated with a ventricular septal defect and an anomalous coronary artery. Tex Heart Inst J 2005;32:555-9.
  37. Dangas G, Mehran R, Feldman D, Stoyioglou A, Pichard AD, Kent KM, Satler LF, Fahy M, Lansky AJ, Stone GW, Leon MB. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. Am J Cardiol 2002;89:586-9.
  38. Dangas G, Mehran R, Kokolis S, Feldman D, Satler LF, Pichard AD, Kent KM, Lansky AJ, Stone GW, Leon MB. Vascular Complications After Percutaneous Coronary Interventions Following Hemostasis With Manual Compression Versus Arteriotomy Closure Devices. J Am Coll Cardiol 2001;38:638-41.
  39. Dangas G, Machac J, Goldman ME, Sharma SK, Shao JH, Cohen AM, Meraj P, Feldman D, Ambrose JA. Evaluation of myocardial viability in asymptomatic patients early postinfarction with perfusion/metabolism SPECT imaging and dobutamine echo-cardiography. Coronary Artery Dis 2000;11:409-14.
  40. Jayasundera TG, Feldman DN, Marmur JD. Tirofiban-induced coronary thrombolysis. J Invasive Cardiology 1999;11:138-140.
  41. Dangas G, Ambrose JA, Sharma SK, Shao JH, Feldman D, Cohen AM, Marmur JD, Cocke TP, Duvvuri S, Goldman ME. The effect of early post-infarction revascularization of asymptomatic patients on left ventricular remodeling. Coronary Artery Dis 1999;10:203-210.
  42. Dangas G, Marmur JD, King TE, DeLeon J, Sharma SK, Vidhun R, Feldman D, Stoynov ME, Badimon JJ, Ambrose JA. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention. Am Heart J 1999;138:49-54.

Honors and Awards

  1. SCAI Emerging Leader Mentorship (ELM) Program Fellowship Recipient (in partnership with ACC and CRF) – 2013-2015
  2. The 5th Annual Department of Medicine Fellow Research Award (NY Presbyterian Weill Cornell Medical Center) - 2007
  3. Dr. Lee A. Winston, Ingersoll-Rand Company Award for the Senior Resident who Best Exemplifies Excellence in Clinical Care, Compassion and Humanitarianism - 2004
  4. Dr. Frederick H. King Medical Merit Scholarship for the Student Possessing the Most Excellent Scholastic Record - 1997-2001
  5. Dr. Henry S. Sacks Research Fellowship(NIH funded) - 1998
  6. Sigma Xi (The Scientific Research Society, NYU Chapter) - 1996
  7. Phi Beta Kappa (Beta Chapter of NY) - 1995
  8. Silverstein Scholarship (Merit Scholarship) - 1994